Related Experiment Videos
Accidental glibenclamide ingestion in an infant: clinical and electroencephalographic aspects
Insights
Severe hypoglycemia in an infant caused by glibenclamide can lead to neurological issues. This case study suggests patchy central nervous system involvement, differing from typical experimental findings in hypoglycemia.
Area of Science:
- Pediatric Neurology
- Clinical Electrophysiology
- Pharmacology
Background:
- Glibenclamide is an oral hypoglycemic agent.
- Severe hypoglycemia can cause neurological damage.
- Infant cases of drug-induced hypoglycemia are rare.
Observation:
- A severe episode of glibenclamide-induced hypoglycemia in an infant was documented.
- Clinical and electroencephalogram (EEG) features were monitored during and after the hypoglycemic event.
- A 12-month follow-up was conducted to assess neurological outcomes.
Findings:
- The infant experienced significant neurological sequelae following the severe hypoglycemic episode.
- EEG data revealed specific patterns associated with the hypoglycemia.
- The observed neurological involvement appeared patchy within the central nervous system.
Implications:
- This case suggests that glibenclamide-induced hypoglycemia may result in a distinct pattern of central nervous system damage.
- Findings challenge existing experimental models of hypoglycemia regarding the extent and nature of neurological sequelae.
- Further research is warranted to understand the specific mechanisms of glibenclamide neurotoxicity in infants.
Abstract:
The clinical and EEG features of an infant during and after a severe episode of glibenclamide-induced hypoglycaemia are reported, with a 12-month follow-up. The very few cases reported in the literature, together with the present report, suggest that the neurological sequelae of severe hypoglycaemia resulting from ingestion of this drug are due to more patchy involvement of the central nervous system than would be expected from experimental work on hypoglycaemia.